Personalized Medicine – Products

Strategic collaborations in molecular residual disease monitoring of cancer and product launches in ddPCR portfolio advance corporate strategy in H1 2024.

To support today’s modern laboratories, Thermo Fisher Scientific is introducing several new columns to meet researchers’ analytical, efficiency, and scalability needs at HPLC 2024, taking place in Denver, CO from July 20 – 25.

Thermo Fisher Scientific Inc. has announced that it has completed its acquisition of Olink Holding AB, a provider of next-generation proteomics solutions.

This case study presents a scalable, automation-friendly workflow for active deparaffinization, extraction and purification of nucleic acids from FFPE samples that can transform cancer diagnostics as demand grows.

Leica Microsystems, has released version 14 of Aivia, its flagship image analysis solution. This update introduces a suite of new features and enhancements for accurate deep-learning based cell segmentation.

At ASMS 2024, SCIEX, introduces ZT Scan DIA for LC-MS/MS, the next generation in data-independent acquisition (DIA) that leverages the combination of the quadrupole dimension with the rich MS2 data attainable from the Zeno trap.

New analytical instruments and workflow capabilities improve productivity, reliability and sensitivity of discovery, translational and clinical research.

Thermo Fisher Scientific Inc. (NYSE: TMO), unveiled the Thermo Scientific™ Stellar™ mass spectrometer (MS), a new solution that combines fast throughput, high sensitivity, and ease of use.

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.

Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.